Results 151 to 160 of about 49,496 (199)
The use of anticholinergic antiparkinson agents in Norway: Epidemiology, toxicology and clinical implications [PDF]
, 2010 This thesis is based on two fundamental questions: Which patients are currently using anticholinergic antiparkinson drugs? Does it matter which anticholinergic antiparkinson drug they are using?
Pål Gjerden
openalex +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Metabolism of antiparkinson agent dopazinol by rat liver microsomes.
Drug Metabolism and Disposition, 1990Metabolism of dopazinol (DZ) by liver microsomes from control and phenobarbital- and 3-methylcholanthrene-treated rats has been investigated. Liver microsomes from control and treated rats metabolized DZ to N-despropyl-DZ (39-53% of total metabolites); 8-hydroxy-DZ, a catechol metabolite (32-39%); and 5- or 6-hydroxy-DZ (12-20%).
K P, Vyas +4 more
openaire +2 more sources
Therapeutic Antagonism between Anticholinergic Antiparkinsonism Agents and Neuroleptics in Schizophrenia [PDF]
Neuropsychobiology, 1979 Systematic data from three studies suggest that anticholinergic antiparkinsonism agents, when added to ongoing neuroleptic treatment in schizophrenics, have the effect of arresting or reversing therapeutic changes, and when given alone to untreated patients, tend to further worsen their psychosis. The countertherapeutic effects of anticholinergic drugs
Stanley R. Kay, Mohan Singh
openaire +2 more sources
Reactions to Antiparkinson Agents
1987The cardiovascular effects are dose-related. Low doses can cause transient bradycardia; moderate or high doses can cause tachycardia, palpitation, and arrhythmias (due to blockage of vagal effects on the S-A node).
Bette L. Okeya +3 more
openaire +2 more sources
Nederlands tijdschrift voor geneeskunde, 1987 A L, Staal-Schreinemachers, J P, Lakke
+5 more sources
Acta Psychiatrica Scandinavica, 1970
SUMMARYA series of four experiments designed to assess the effect of antiparkin‐sonism drugs on phenothiazine produced parkinsonism are described. It was difficult to distinguish the effects of the active drug from placebo when intravenous injections were employed, but using handwriting as an indication it was possible to distinguish the oral ...
openaire +3 more sources
SUMMARYA series of four experiments designed to assess the effect of antiparkin‐sonism drugs on phenothiazine produced parkinsonism are described. It was difficult to distinguish the effects of the active drug from placebo when intravenous injections were employed, but using handwriting as an indication it was possible to distinguish the oral ...
openaire +3 more sources
[The use of synthetic antiparkinson agents as antidepressive agents].
Annales medico-psychologiques, 1979 Wirth Jf
openaire +2 more sources
[Considerations on projected pharmacology of antiparkinson agents].
Therapie, 1969 P, Duchene-Marullaz, M, Jalfre, J, Hache
openaire +2 more sources
Pharmacology Biochemistry and Behavior, 2008
Antiparkinson agents possess excellent anticonvulsant properties against nerve agent-induced seizures by exerting both cholinergic and glutamatergic antagonisms. It is important, however, that drugs used as prophylactics not by themselves cause impairment of cognitive capability.
Siri Enger, Trond Myhrer, Pål Aas
openaire +3 more sources
Antiparkinson agents possess excellent anticonvulsant properties against nerve agent-induced seizures by exerting both cholinergic and glutamatergic antagonisms. It is important, however, that drugs used as prophylactics not by themselves cause impairment of cognitive capability.
Siri Enger, Trond Myhrer, Pål Aas
openaire +3 more sources